A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Shun Lu(Shanghai Jiao Tong University), Yusuke Okuma(Unknown), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Zoran Andrić(University Hospital Medical Center Bezanijska kosa), Jorge Alatorre-Alexander, Joaquim Bosch‐Barrera(Universitat de Girona), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Robert M. Jotte(Sarah Cannon), Firas Badin, Jun Cai(Guangzhou University of Chinese Medicine), Haralabos P. Kalofonos(University of Patras), Reyes Bernabé(Hospital Universitario de Valme), Makoto Nishio(Japanese Foundation For Cancer Research), Jonathan W. Riess(University of California Davis Medical Center), Bo Wang(Xi'an Jiaotong University), Hui Wang(Central South University), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Yan Yu(Binzhou Medical University), Nathan A. Pennell(Cleveland Clinic)
Cited by 2
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k